West Pharma (WST) Tops Q2 EPS by 33c, provides guidance
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $370.44 -0.85%
Revenue Growth %: +2.6%
Financial Fact:
Interest income: 200K
Today's EPS Names:
OCCI, IPX, ALZN, More
Revenue Growth %: +2.6%
Financial Fact:
Interest income: 200K
Today's EPS Names:
OCCI, IPX, ALZN, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q2 EPS of $1.84, $0.33 better than the analyst estimate of $1.51. Revenue for the quarter came in at $766.5 million versus the consensus estimate of $725.26 million.
GUIDANCE:
West Pharma sees FY2025 EPS of $6.65-$6.85, versus the consensus of $6.27.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
- HeartSciences (HSCS) files $200M mixed shelf
- Goldcana closes C$2M private placement, issues 8M units
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
